SDx: Inventors of Dynamic Flux Amplification (DFA)About Us
What are we doing?
Signal Diagnostics specializes in the design and deployment of molecular diagnostics for human, animal, and plant diseases and pathogens.Signal Diagnostics developed a patent pending process to amplify DNA, and RNA--Dynamic Flux Amplification (DFA). The process is unique to the biochemistry world, in that it is capable of generating highly specific and highly sensitive amplified nucleic acids, and the results can be scored by any desired detection method: Gel, endpoint fluorescence, Immuno-assay, and even real-time PCR based detection. Our expert development team is regularly working on new target applications. You can get your own on our Products page.
Our other patent pending technique involves the implementation of HRM (high resolution melting) to generate drug resistance profiles for a variety of human diseases. The technology, has applications throughout the molecular biology and biochemistry community.
SDx Company History
2009: Dynamic Flux Amplification technology launch2008: Patent Application for Novel Drug Resistance in human disease filed
2008: Patent Appliation
2008: Company Founded
Management Team
- Brian Erich Caplin, Ph.D., President/CEO/CSO
- Dale Richards, MBA, ChE, AVA, Business Manager
- Stephen Caplin, JD, General Counsel
Signal Diagnostics, Inc.
2700 West Homestead Road
Suite 50
Park City, UT 84098
(801) 580-0490
FAX (800) 808-0490
becaplin@signaldiag.com
2700 West Homestead Road
Suite 50
Park City, UT 84098
(801) 580-0490FAX (800) 808-0490
becaplin@signaldiag.com
